DPO-1

• Catalog No.: D7443
• CAS Number: 43077-30-1
• M. F.: C22H29OP
• M. W.: 340.438821
• Purity: >97% (NMR)
• Storage: protect from light

SYNONYMS

• IUPAC name: {[(1S,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyl](phenyl)phosphoroso}benzene
• IUPAC Traditional name: [(1S,2S,5R)-2-isopropyl-5-methylcyclohexyl(phenyl)phosphoroso]benzene
• Synonyms: (1S,2S,5R)-5-Methyl-2-(1-methylethyl)cyclohexyl]diphenyl-phosphine oxide; (+)-Neomenthyl diphenylphosphine oxide

DATABASE IDS

• MDL Number: MFCD09038567
• CAS Number: 43077-30-1

PROPERTIES

• Empirical Formula (Hill Notation): C22H29OP
• Purity: >97% (NMR)
• Apperance: white needles
• Solubility: DMSO: >5 mg/mL at ~60 °C, clear
• Personal Protective Equipment: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
• Storage Condition: protect from light
• Storage Temperature: 2-8°C
• German water hazard class: 3

DETAILS

Description (English)

Biochem/physiol Actions
DPO-1 is an inhibitor of human Kv1.5 potassium channel; representative blocker of a novel pharmacophore. The Kv1.5 potassium channel, which underlies the ultrarapid delayed rectifier current, IKur, is reported to be enriched in human atrium versus ventricle, and has been proposed as a target for novel atrial antiarrhythmic therapy. The administration of the IKur blocker (2-isopropyl-5-methyl-cyclohexyl) diphenylphosphine oxide (DPO-1) increases myocardial refractoriness in both atrium and ventricle of rat, but produces an atrial-selective increase in refractoriness in primates; appears to be 15-fold more selective for Kv1.5 vs Kv3.1 channels expressed in Xenopus oocytes. IC50 = 0.16-0.76 μM at 0.1 Hz pulsing frequency; Kd = 0.6 μM.

Description (简体中文)

Biochem/physiol Actions
DPO-1 is an inhibitor of human Kv1.5 potassium channel; representative blocker of a novel pharmacophore. The Kv1.5 potassium channel, which underlies the ultrarapid delayed rectifier current, IKur, is reported to be enriched in human atrium versus ventricle, and has been proposed as a target for novel atrial antiarrhythmic therapy. The administration of the IKur blocker (2-isopropyl-5-methyl-cyclohexyl) diphenylphosphine oxide (DPO-1) increases myocardial refractoriness in both atrium and ventricle of rat, but produces an atrial-selective increase in refractoriness in primates; appears to be 15-fold more selective for Kv1.5 vs Kv3.1 channels expressed in Xenopus oocytes. IC50 = 0.16-0.76 μM at 0.1 Hz pulsing frequency; Kd = 0.6 μM.